

REMARKS/ARGUMENTS

Claims 24-35 and 38-60 are pending in the present application. Claims 29, 30, 33-35, 41, 42, 46, 48, 52, 53 and 55-58 have been withdrawn from consideration. Claims 1-23, 36 and 37 have been canceled without prejudice or disclaimer. Claims 24 and 25 have been amended by this Amendment.

Claim Rejections under 35 USC § 102 and 35 USC § 103

Claims 24-28, 31, 32, 38-41, 44, 45, 47, 49-51 and 54 stand rejected under 35 USC § 102(b) as anticipated by Adeyinka et al. (Clin. Cancer Res., vol. 78, pp. 3788-3795, 2002, hereinafter "Adeyinka"). Claims 36 and 37 stand rejected under 35 USC § 103(a) as unpatentable over Adeyinka in view of Sgroi et al. (Cancer Res., vol. 59, pp. 5656-5661, 1999, hereinafter "Sgroi"). Claims 59 and 60 stand rejected under 35 USC § 103(a) as unpatentable over Adeyinka and Erlander et al. (US 2003/0186248, hereinafter "Erlander"). Applicants respectfully traverse these rejections.

Discussion of Disclosed Embodiments

The following descriptive details are based on the specification. They are provided only for the convenience of the Examiner as part of the discussion presented herein, and are not intended to argue limitations which are unclaimed.

Applicants' disclosed embodiments are directed to reducing an error which is caused by healthy tissue in a sample to be analyzed. Two sections of a microtome section series of a tissue sample that are not immediately adjacent to each other are stained and evaluated histologically/cytologically, while other sections of the microtome section series that are located

between these two sections in the original tissue sample are homogenized and subjected, for example, to an array-based mRNA analysis. The number of sections used for the array-based mRNA analysis depends, for example, on the amount of mRNA required for the analysis. (see, e.g., paragraph [0054] of the application as originally filed).

The tissue-specific composition of the two flanking sections is thus known, and the molecular-biological characteristics of the one or more sections located between the flanking sections in the original tissues sample are also known. The quantitative fraction, the appearance, and/or the distribution pattern of the diseased tissue or diseased cells in the sections or sections analyzed by the molecular-biological methods can thus be more reliably determined. (see, e.g., paragraphs [0055]-[0057] of the application as originally filed).

Similar advantages apply to disclosed embodiments in which the divided samples, i.e., samples or portions of samples, that are sent for histological/cytological examination are selected to ensure that the one or more divided samples sent for non-morphological analytical testing were located between these divided samples in situ. (see paragraph [0058] of the application as originally filed).

Arguments

The art cited by the Examiner fails to disclose, teach or suggest “two of the prepared sections are subjected to the histological/cytological examination, and the two of the prepared sections are selected so that the at least another one of the prepared sections subjected to the non-morphological analytical testing is between the two of the prepared sections in situ”, as expressly recited by Applicants’ independent claim 24. This limitation of independent claim 24 was originally recited in now canceled claim 36.

The Examiner acknowledges at page 5 of the Office Action that Adeyinka fails to teach or suggest using tissue sections adjacent to sections used for non-morphological testing for histological/cytological examination. The Examiner instead relies on Sgroi as teaching these features to assert that a combination of Adeyinka and Sgroi discloses the features of Applicants' now canceled claims 36 and 37.

Sgroi describes analysis of tissue sections from a breast cancer using histology and microarray hybridization. Immunohistochemical staining of frozen tissue sections adjacent to slides used for laser capture microdissection (LCM) is performed (See p. 5657, col. 2, first paragraph of Sgroi).

Sgroi fails to teach or suggest that the immunohistochemical staining is performed on a slide of a tissue sample between two slides of tissue samples used for the LCM. To the contrary, Sgroi teaches only immunohistochemical staining of frozen tissue sections adjacent to slides used for laser capture microdissection (LCM). Immunohistochemical staining of a merely adjacent slide does not allow for a more reliable determination because a tissue fraction range cannot be determined from slides that are merely adjacent. The two of prepared sections instead must be selected so that the at least another one of the prepared sections subjected to the non-morphological analytical testing is between the two of the prepared sections in situ, i.e., in the original sample tissue. Sgroi therefore fails to disclose, teach or suggest "two of the prepared sections are subjected to the histological/cytological examination, and the two of the prepared sections are selected so that the at least another one of the prepared sections subjected to the non-morphological analytical testing is between the two of the prepared sections in situ", as expressly recited by Applicants' independent claim 24.

Even assuming, *arguendo*, the propriety of the Examiner's proffered combination of Adeyinka, Sgroi and Erlander (which Applicants do not concede), Erlander fails to cure the deficiencies of Adeyinka and Sgroi discussed above with respect to independent claim 24. Erlander simply describes the use of molecular histological signatures to interpret and correlate cytological specimens, and fails to disclose, teach or suggest at least another one of the prepared sections subjected to the non-morphological analytical testing is between the two of the prepared sections *in situ*.

Independent claim 24 is accordingly deemed to be patentably distinct over the cited art for at least the foregoing reasons.

Independent claim 25 contains features akin to those discussed above with respect to claim 24 and, therefore, claim 25 is likewise deemed to be patentably distinct over the cited art for at least the same reasons as is claim 24. Claims 26-35 and 38-60, which variously depend from one of claims 24 and 25, are deemed to be patentably distinct over the cited art for at least the same reasons as are claims 24 and 25, as well as on their own merits.

In view of the foregoing, Applicants respectfully request that the rejections under 35 USC § 102 and 35 USC § 103 be withdrawn.

CONCLUSION

In view of the foregoing, reconsideration and withdrawal of all rejections, and allowance of all pending claims is respectfully solicited.

It is believed that no fees or charges are required at this time in connection with the present application. However, if any fees or charges are required at this time, they may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,
COHEN PONTANI LIEBERMAN & PAVANE LLP

By /Alfred W. Froebrich/
Alfred W. Froebrich
Reg. No. 38,887
551 Fifth Avenue, Suite 1210
New York, New York 10176
(212) 687-2770

Dated: March 1, 2010